Bioventus' acquisition activities so far this year total more than $1 billion. Its most recent plans were announced Aug. 30.
Here's what you should know about each deal:
1. Bioventus acquired Bioness in March for $45 million.
2. Bioness is a company focused on helping patients regain mobility after a stroke, traumatic brain injury, multiple sclerosis and osteoarthritis.
3. The acquisition includes a six-device portfolio of peripheral nerve stimulation therapy technology sold in 40 countries worldwide.
4. Bioventus announced plans to acquire Misonix in a $518 million deal in July.
5. The acquisition will augment Bioventus' lower extremity offerings and commercial footprint. It's also expected to accelerate Misonix's BoneScalpel and Nexus adoption and extend its international access.
6. The acquisition is expected to close in the fourth quarter of 2021 and add almost $80 million in revenue.
7. Bioventus plans to acquire CartiHeal, an Israeli medtech company for $500 million. As part of its option and equity purchase agreement with CartiHeal, the company is making a $50 million escrow payment, signaling its intent to proceed with the acquisition.
8. The decision was made after reviewing a clinical trial of CartiHeal's Agili-C implant, designed for the treatment of cartilage and osteochondral defects in the knee joint in patients without severe osteoarthritis.
9. The option may only be exercised pending FDA premarket approval of Agili-C. The clinical module of its premarket approval is expected to be submitted later this year.